Journal of Cardiac Failure
Volume 13, Issue 4 , Pages 304-311 , May 2007

Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy

  • Srinivas Iyengar, MD

      Affiliations

    • From the Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • Corresponding Author InformationReprint requests: Srinivas Iyengar, MD, Division of Cardiovascular Medicine, The OSU Heart Center, 473 West 12th Avenue, Columbus, OH 43210-1252.
    • ,
  • Garrie Haas, MD, FACC

      Affiliations

    • From the Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • ,
  • Sumant Lamba, MD, FACC

      Affiliations

    • From the Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • ,
  • David A. Orsinelli, MD, FACC

      Affiliations

    • From the Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • ,
  • Gopal J. Babu, PhD

      Affiliations

    • The Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • ,
  • Amy K. Ferketich, PhD

      Affiliations

    • The Division of Epidemiology, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • ,
  • Laura Yamokoski, RN

      Affiliations

    • From the Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • ,
  • Muthu Periasamy, PhD

      Affiliations

    • The Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio
    • ,
  • William T. Abraham, MD, FACC

      Affiliations

    • From the Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio
    • The Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio
    • The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio

Received 25 July 2006 ,Revised 28 November 2006 ,Accepted 24 January 2007.

References 

  1. Gras D, Leclercq C, Tang A, et al. Cardiac resynchronization therapy in advanced heart failure: the multicenter InSync clinical study. Eur J Heart Fail. 2002;4:311–320
  2. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. The Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. N Engl J Med. 2001;344:873–880
  3. Abraham WT, Fisher WG, Smith AL, et al. for the MIRACLE study group Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–1853
  4. Auricchio A, Stellbrink C, Sack S. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026–2033
  5. Saxon LA, Boehmer JP, Hummel J, et al. Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. The VIGOR CHF and VENTAK CHF Investigators. Am J Cardiol. 1999;83:120D–130D
  6. Bristow MR, Saxon LA, Boehmer JP, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  7. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549
  8. St. John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart. For the MIRACLE study group. Circulation. 2003;107:1985–1990
  9. Saxon LA, DeMarco T, Schafer J, et al. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation. 2002;105:1304–1310
  10. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431–438
  11. Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999;83:1201–1205
  12. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112:1580–1586
  13. Bristow MR, Mestroni L, Bohlmeyer TJ, Gilbert EM. Dilated cardiomyopathies. In:  Fuster V,  Alexander RW,  O'Rourke RA editor. 10th ed.. Hurst's the heart. Vol. 2:New York: McGraw-Hill; 2001;p. 1947–1966
  14. Schwartz K, Chassagne C, Boheler KR. The molecular biology of heart failure. J Am Coll Cardiol. 1993;22(Suppl A):30A–33A
  15. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997;80(Suppl):15L–25L
  16. Mercadier JJ, Lompre AM, Duc P, et al. Altered sarcoplasmic reticulum Ca-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990;85:305–309
  17. Nakao K, Minobe WA, Roden RL, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 1997;100:2362–2370
  18. Lowes BD, Minobe WA, Abraham WT, et al. Changes in gene expression in the intact human heart: down regulation of α-myosin heavy chain in hypertrophied, failing left ventricular myocardium. J Clin Invest. 1997;100:2315–2324
  19. Abraham WT, Gilbert EM, Lowes BD, et al. Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med. 2002;8:750–760
  20. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002;346:1357–1365
  21. Heerdt PM, Holmes JW, Cai B, et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation. 2000;102:2713–2719
  22. Mason JW. Techniques for right and left ventricular endomyocardial biopsy. Am J Cardiol. 1978;41:887–892
  23. Uemura N, Ohkusa T, Hamano K, et al. Down-regulation of sarcolipin mRNA expression in chronic atrial fibrillation. Eur J Clin Invest. 2004;34:723–730
  24. Helmcke F, Nanda NC, Hsuing MC, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation. 1987;75:175–183
  25. Cappola TP, Harsch MR, Jessup M, et al. Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender. J Card Fail. 2006;12:182–188
  26. Feldman AM, Ray PA, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation. 1991;83:1866–1872
  27. Frank KF, Bolck B, Erdmann E, Schwinger RHG. Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation. Cardiovasc Res. 2003;57:20–27
  28. Yasumura Y, Takemure K, Sakamoto A, Kitakaze M, Miyatake K. Changes in myocardial gene expression associated with beta-blocker therapy in patients with chronic heart failure. J Card Fail. 2003;9:469–474
  29. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003;42:1666–1673
  30. Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan. Mol Cell Biochem. 2003;254:163–172
  31. Plank DM, Yatani A, Ritsu H, et al. Calcium dynamics in the failing heart: restoration by beta-adrenergic receptor blockade. Am J Physiol Heart Circ Physiol. 2003;285(Suppl 1):H305–H315
  32. Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJ. Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol. 2003;41:1096–1106
  33. Chen Y, Park S, Li Y, et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics. 2003;14:251–260
  34. Sabbah HN. Effects of cardiac support device on reverse remodeling: molecular, biochemical, and structural mechanisms. J Card Fail. 2004;10(Suppl):S207–S214
  35. Del Monte F, Johnson CM, Stepanek AC, Doye AA, Gwathmey JK. Defects in calcium control. J Card Fail. 2002;8(Suppl):S421–S431
  36. Spragg DD, Leclercq C, Loghmani M, et al. Regional alterations in protein expression in the dyssynchronous failing heart. Circulation. 2003;108:929–932

 Funded, in part, by a Heart Failure Society of America Fellow Research Award that supported Dr. Iyengar during the conduct of this investigation and by research funds from The Ohio State University Division of Cardiovascular Medicine.

PII: S1071-9164(07)00006-1

doi: 10.1016/j.cardfail.2007.01.005

Journal of Cardiac Failure
Volume 13, Issue 4 , Pages 304-311 , May 2007

Article Tools

* Image Usage & Resolution